Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
More Reading from MarketBeat A Fresh IPO That Long-Term Investors Shouldn't IgnoreAuthor: Jordan Chussler. Article Published: 1/14/2026. 
Quick Look - While IPOs are often labeled as high-risk startups, some are worthy of more conservative investors’ attention.
- Aktis Oncology’s IPO—the first biotech IPO of 2026—resulted in a $318 million raise, with the biotech firm receiving $100 million in backing from Big Pharma giant Eli Lilly.
- The company, which now has a market cap of $3.34 billion, develops radiopharmaceuticals and is positioned for long-term success after being listed on the Nasdaq.
For speculative investors, the start of each year is always a good time to revisit an initial public offering (IPO) calendar. Almost every week, companies go public, with a handful of them offering considerable short-term upside potential. Of course, they also carry substantial downside risk. But even for conservative investors who err on the side of caution, some stocks that have recently IPO’ed shouldn’t be overlooked, as they may justify a place in buy-and-hold portfolios. A little-known government task force just wrapped up a 20-year project, and its findings could unlock access to a massive U.S. national asset. Under existing law, everyday Americans may now have a legal path to participate in what some are calling a once-in-a-generation opportunity.
Details are still flying under the radar, but that may not last. See the full briefing and how it works For one biotechnology company in the healthcare sector that just went public, that may be the case. Last Year’s IPO Success Stories Last year serves as a strong example of why these companies shouldn’t be dismissed by investors with lower risk tolerances. AI cloud computing provider CoreWeave (NASDAQ: CRWV), which went public in March 2025, is up nearly 123% since then. While short-term speculators may have capitalized on its nearly 359% gain before hitting 30 days listed on the Nasdaq, those who hung in are still enjoying strong returns. Others, such as Medline (NASDAQ: MDLN), refute the misconception that IPOs are all high-risk startups. The medical products and services provider, which publicly debuted in December 2025, was founded in 1966 and already boasts a market cap in excess of $55 billion. Similarly, Smithfield Foods (NASDAQ: SFD)—famous for its ubiquitous packages of bacon—waited 89 years before its IPO. Since going public in January 2025, the stock is up nearly 5%, but it has also rewarded shareholders with a dividend that currently yields 4.44%, or $1 per share annually, making it an immediate consideration for income investors. After its IPO and with shares hitting the market on Jan. 9, Aktis Oncology (NASDAQ: AKTS), a maker of radiopharmaceuticals, is hoping for a similar outcome in 2026 and beyond. Why Are Radiopharmaceuticals Important? Aktis Oncology specializes in radiopharmaceuticals—a subset of nuclear medicine that uses radioactive drugs for both diagnostics and the treatment of conditions including cancer, heart disease and neurological disorders. Radiopharmaceuticals combine radioactive isotopes with a targeting module that can seek out particular cells (for example, cancer cells) to deliver localized doses of radiation, minimizing harm to healthy tissue that could be affected by conventional radiology treatments. According to industry consultancy firm Grand View Research, the global nuclear medicine market, estimated at nearly $18 billion in 2024, is forecast to reach nearly $35 billion by 2030—a compound annual growth rate of 10.16%. Importantly for Boston-based Aktis Oncology, Grand View Research notes that the North American segment accounts for nearly 43% of the global nuclear medicine market, with the United States as the predominant player. Aktis Oncology’s Clinical-Stage Platform Wall Street is expecting biotech IPOs to rebound in 2026 after funding cuts by the Trump administration notably slowed listings from the healthcare sector in 2025. Aktis Oncology, which debuted on the Nasdaq on Jan. 9, marked the first biotech IPO of 2026 and produced one of the largest biotech IPO raises in recent memory. With $318 million raised in the offering, the firm now has a market capitalization of about $3.34 billion. According to the company’s prospectus, its executive team includes experts in drug development, approval and commercialization, with members of management having participated in bringing 14 currently FDA-approved products to market. At a technical level, Aktis develops targeted alpha radiopharmaceuticals, a class of precision cancer drugs that use proprietary technology to target solid tumors while sparing healthy tissue. Aktis Oncology’s Eli Lilly Connection Aktis is a clinical-stage, pre-revenue company, but that did not prevent it from attracting a high-profile backer: Eli Lilly (NYSE: LLY) anchored the IPO. According to Reuters, Eli Lilly purchased $100 million worth of AKTS shares in the offering. That investment builds on a partnership announced in 2024 in which Eli Lilly committed $60 million in cash and an equity investment to collaborate on tumor-targeting radiopharmaceuticals, with potential milestone payments that could exceed $1 billion. The significance of Eli Lilly’s backing cannot be overstated. At about $1.01 trillion in market cap, Lilly is one of the largest Big Pharma companies, after the company’s net income jumped nearly 109% year-over-year from 2023 to 2024. That trend is likely to be a focus when Eli Lilly reports Q4 and full-year 2025 financials on Feb. 5. Between its equity stake and the recent $100 million in AKTS shares purchased at the IPO, the maker of Zepbound now has a sizable financial interest in the biotech startup’s success.
| 
